Live Breaking News & Updates on Msi H

Stay updated with breaking news from Msi h. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC

First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy. ....

United States , San Antonio , University Of Texas , France General , Bristol Myers Squibb , Neil Newman , Thierry Andre , Mark Lewis , Drug Administration , University Of Texas Health Science Center , Sorbonne University , Clinical Oncology Gastrointestinal Cancers , Texas Health Science Center , Intermountain Healthcare , Medscape Medical News , Colorectal Cancer , Colorectal Cancer Crc , Biologic Therapy , Metastatic Colorectal Cancer , Metastatic Crc , Etastatic Colorectal Cancer Mcrc , Microsatellite Instability High , Microsatellite Instability High , Micro Satellite Instability High , Msi H , Microsatellite Instability ,

FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer

The approval moves dostarlimab s endometrial cancer indication earlier in the treatment paradigm. ....

Hesham Abdullah , Drug Administration , Rxdx Panel , Endometrial Carcinoma , Alignant Neoplasia , Reproductive Health , Drug Development , Womens Health , Reproductive Endocrinology , Combination Chemotherapy , Microsatellite Instability High , Microsatellite Instability High , Micro Satellite Instability High , Msi H , Microsatellite Instability , Us Food And Drug A ,

FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer. ....

New England Journal , Dostarlimab Plus Chemotherapy , Endometrial Cancer , Msi H , Gynecologic Cancer , Priority Review , Mismatch Repair Deficient , Microsatellite Instability High , Ruby Study , Ruby Engot Eng Gog3031 Nsgo , New England Journal Of Medicine ,

EMA Validates Type II Variation Application for Dostarlimab/Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

The European Medicines Agency has validated a type II variation for potential approval of dostarlimab in combination with carboplatin and paclitaxel for the treatment of patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer. ....

Hesham Abdullah , European Medicines Agency , Committee For Medicinal Products Human , Medicinal Products , Human Use , New England Journal , Medicines Agency , Endometrial Cancer , Msi H , Ruby Trial ,

'Home Run': Immunotherapy Add-on for Advanced Endometrial Cancer

Two new studies show that adding immunotherapy with pembrolizumab or dostarlimab to chemotherapy significantly boosts progression-free survival in patients with advanced endometrial cancer. ....

United States , San Diego , Bhavana Pothuri , Daiichi Sankyo , Ramezn Eskander , Rebeccac Arend , Mansoorr Mirza , European Union , Merck Co , Copenhagen University Hospital , Ob Gyn Reproductive Sciences , York University Langone Perlmutter Cancer Center , Zai Lab , University Of Alabama At Birmingham , Society Of Gynecologic Oncology , National Cancer Institute , University Of California , Oneal Comprehensive Cancer Center , Department Of Oncology , Gynecologic Oncology , New England Journal , O Neal Comprehensive Cancer Center , Already Approved , Reproductive Sciences , Cooperative Research , Developmental Agreement ,